FDA Approves Casgevy  (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease

– First-ever approval of a CRISPR-based gene-editing therapy in the U.S. – Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news